Cogent Biosciences, Inc. (COGT) NASDAQ

32.90

-1.91(-5.49%)

Updated at June 02 03:49PM

Currency In USD

About Privacy Policy Contact us Terms & Conditions

Cogent Biosciences, Inc.

Address

200 Cambridge Park Drive

Waltham, MA 02140

United States of America (the)

Phone

617 945 5576

Website

https://www.cogentbio.com

Sector

Healthcare

Industry

Biotechnology

Employees

205

First IPO Date

March 29, 2018

Key Executives

Name	Title	Pay	Year Born
Andrew R. Robbins	President, Chief Executive Officer & Director	1.32M	1976
Cole Pinnow	Chief Commercial Officer	754,602	1975
John L. Green	Chief Financial Officer & Principal Accounting Officer	834,275	1980
John Edward Robinson	Chief Scientific Officer	868,743	1974
Jessica Sachs	Chief Medical Officer	896,623	1975
Evan D. Kearns	Chief Legal Officer & Corporate Secretary	0	1980
Brad Barnett	Chief Technology Officer	0	N/A
Brad Fell	Senior Vice President of Chemistry	0	N/A
Rachael Easton	Senior Vice President of Clinical Development	0	N/A
Abb Hayden	Senior Vice President of Sales	0	N/A
Dana R. Martin	Senior Vice President of Medical Affairs & Chief Patient Officer	0	N/A
Christi Waarich	Senior Director of Investor Relations	0	N/A
Erin Schellhammer	Chief People Officer	0	N/A

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.